



## Tumor Necrosis Factor: Molecular Insights and Clinical Implications

Guest Editor:

**Dr. Lorraine A. O'Reilly**  
The Walter and Eliza Hall  
Institute of Medical Research,  
Parkville, VIC 3052, Australia

Deadline for manuscript  
submissions:  
**closed (31 October 2023)**

### Message from the Guest Editor

Tumour necrosis factor-alpha (TNF/TNF $\alpha$ ) as the foremost pro-inflammatory cytokine is a pivotal regulator of conventional innate and adaptive immune responses, with diverse functions in cellular processes such as differentiation, proliferation, inflammation, apoptosis and necroptosis. Since its discovery nearly 40 years ago, the TNF superfamily has grown to 19 members, with 29 interacting receptors and multiple scaffolding proteins. Binding of TNF to either TNFR1 or TNFR2 mediates the activation of tightly regulated and complex downstream signalling cascades, resulting in cell death or activation of the transcription factors NF- $\kappa$ B (Nuclear Factor-KappaB) and AP-1 (Activation Protein-1).

In this Special Issue, we would like to highlight and discuss the success and challenges of newer therapeutic approaches aimed at manipulating TNF signalling for cancer therapy. Such therapies are not limited to IAP inhibitors, antagonistic TNFR2 antibodies and various combinative approaches with immunotherapies or therapy related to TNF or other members of the TNF superfamily to improve clinical outcomes.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)